HomeAI · summaries
Storia in 5 fonti
Sanofi, once on FDA course for speedy approval, gains late expansion for Tzield
After accepting Sanofi’s application for an expansion of its Type 1 diabetes treatment Tzield and putting it in the fast lane for a potential approval under a controversial new pathway, the FDA has | Sanofi has gained an FDA expansion for its Type 1 diabetes treatment Tzield. The decision came nearly two months after an original target date under former FDA chief Marty Makary’s controversial Commissioner’s National Priority Voucher (CNPV) program.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
- ·
thehindubusinessline.com
US FDA approves expanded use of Sanofi's type 1 diabetes drug
The FDA approves Sanofi’s Tzield for type 1 diabetes, now available for children aged 8-17 recently diagnosed with stage 3.
